Lv2
160 积分 2024-04-15 加入
Epidemiology and determinants of obesity in China
17天前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
1个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
1个月前
已完结
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Disease modifying therapies in diabetes and endocrinology
2个月前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
2个月前
已完结
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
3个月前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
3个月前
已完结
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
3个月前
已完结
European expert consensus statement on therapeutic goals in Fabry disease
3个月前
已完结
皖公网安备34019202002308
